In conclusion, our study demonstrated that YTHDF2 was an independent prognostic factor in MM that could promote tumor growth and cell cycle transition via the EGR1/p21cip1/waf1/CDK2-Cyclin E1 axis, highlighting that YTHDF2 could be used as a potential biomarker for predicting prognosis and a promising therapeutic target in MM. This evidence concerns the gene YTHDF2 and Miyoshi myopathy.